此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

Safety and Efficacy Iodofiltic Acid I 123 in the Treatment of Acute Coronary Syndrome (Zeus-ACS)

2016年2月29日 更新者：Molecular Insight Pharmaceuticals, Inc.

Open-label, Phase 2 Study of the Safety and Efficacy of B-methyl-P-(123I)- Iodophenyl-pentadecanoic Acid (Iodofiltic Acid I 123) For Identification of Ischemic Myocardium Using Single Photon Emission Computed Tomography (Spect) in Adults With Symptoms Consistent With Acute Coronary Syndrome (ACS).

This is an open-label phase 2 study recruiting low, moderate, and high likelihood ACS patients from approximately 60 centers. Patients will be imaged with iodofiltic acid I 123 for the detection of myocardial ischemia. Readers independent of the clinical study centers will review results of imaging studies in a blinded fashion at an imaging core lab. The resulting independent reading of the images will be compared against the truth standard for ACS.

研究概览

地位

完全的

条件

干预/治疗

研究类型

介入性

注册 (实际的)

510

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习地点

  • 加拿大
    • British Columbia
      • North Vancouver、British Columbia、加拿大
    • Ontario
      • Scarborough、Ontario、加拿大
  • 美国
    • Alabama
      • Birmingham、Alabama、美国
      • Huntsville、Alabama、美国
    • Arizona
      • Mesa、Arizona、美国
    • California
      • Los Angeles、California、美国
      • Mission Viejo、California、美国
      • Newport Beach、California、美国
      • Roseville、California、美国、95661
    • Connecticut
      • Hartford、Connecticut、美国
      • New Haven、Connecticut、美国
    • Delaware
      • Newark、Delaware、美国
    • Florida
      • Jacksonville、Florida、美国
    • Illinois
      • Aurora、Illinois、美国
      • Maywood、Illinois、美国
    • Kentucky
      • Louisville、Kentucky、美国、40207
    • Maine
      • Auburn、Maine、美国
    • Maryland
      • Bethesda、Maryland、美国
    • Michigan
      • Detroit、Michigan、美国
      • Royal Oak、Michigan、美国
      • Troy、Michigan、美国、48085
    • Minnesota
      • Minneapolis、Minnesota、美国
    • Missouri
      • Kansas City、Missouri、美国、64111
    • New Hampshire
      • Lebanon、New Hampshire、美国
      • Manchester、New Hampshire、美国
    • New York
      • Albany、New York、美国
      • Brooklyn、New York、美国
      • Kingston、New York、美国
      • New York、New York、美国
      • Rochester、New York、美国
      • Syracuse、New York、美国、13210
    • Ohio
      • Cincinnati、Ohio、美国
      • Cleveland、Ohio、美国
      • Columbus、Ohio、美国
    • Rhode Island
      • Providence、Rhode Island、美国
    • Texas
      • Houston、Texas、美国
    • Virginia
      • Richmond、Virginia、美国
    • Wisconsin
      • Madison、Wisconsin、美国

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

40年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Provide written informed consent and are willing to comply with protocol requirements
  • Are 40 years of age or older.
  • Are being evaluated for possible ACS.
  • If female, then not of childbearing potential as documented by history or has a negative serum or urine pregnancy test within 4 hours prior to receiving the test drug and agrees to use an acceptable form of birth control.

Exclusion Criteria:

  • <40 years of age.
  • Females who are pregnant or lactating.
  • History of left ventricular ejection fraction (LVEF)=40%.
  • History of MI.
  • Acute ST segment elevation on ECG.
  • Left bundle branch block on ECG.
  • Known history of significant allergy to x-ray contrast media or iodine/iodides.
  • Currently or formerly on medication that targets fatty acid uptake or metabolism, eg ranolazine, (Ranexa).
  • Administered radiopharmaceutical other than rubidium-82 or thallium-201 within 2 days prior to study enrollment.
  • Underwent cardiac stress testing of any kind within 2 days prior to study enrollment.
  • Serum creatinine level >2.0 mg per dL.
  • Received investigational compound and/or medical device within 30 days of admission into this study.
  • Q-wave abnormalities consistent with previous MI

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：治疗
  • 分配：不适用
  • 介入模型：单组作业
  • 屏蔽：无（打开标签）

武器和干预

参与者组/臂
干预/治疗
实验性的：Iodofiltic Acid I 123
药品：Iodofiltic acid I 123

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Sensitivity, Specificity of Detecting Myocardial Ischemia (Reader 1)
大体时间：Day 30

Enrolled subjects were imaged (10 minutes post-injection) using iodofiltic acid I 123 SPECT and the resulting data were reviewed in blinded reads by readers independent of the study centers and the Sponsor. The results obtained in these blinded reads were compared with the final diagnosis for each subject with regard to myocardial ischemia or ACS, determined by the Final Diagnosis Clinical Endpoints Committee (FDCEC).

Sensitivity = % (n/N): N = number of subjects positive for ischemia per the FDCEC; n = subset of N positive for ischemia per the blinded Majority Read (two of three readers) of iodofiltic acid I 123 readers.

Specificity = % (n/N): N = number of subjects negative for ischemia per the FDCEC; n = subset of N negative for ischemia per the blinded Majority Read (two of three readers) of iodofiltic acid I 123 readers.
Day 30
Sensitivity, Specificity of Detecting Myocardial Ischemia (Reader 2)
大体时间：Day 30

Enrolled subjects were imaged (10 minutes post-injection) using iodofiltic acid I 123 SPECT and the resulting data were reviewed in blinded reads by readers independent of the study centers and the Sponsor. The results obtained in these blinded reads were compared with the final diagnosis for each subject with regard to myocardial ischemia or ACS, determined by the Final Diagnosis Clinical Endpoints Committee (FDCEC).

Sensitivity = % (n/N): N = number of subjects positive for ischemia per the FDCEC; n = subset of N positive for ischemia per the blinded Majority Read (two of three readers) of iodofiltic acid I 123 readers.

Specificity = % (n/N): N = number of subjects negative for ischemia per the FDCEC; n = subset of N negative for ischemia per the blinded Majority Read (two of three readers) of iodofiltic acid I 123 readers.
Day 30
Sensitivity, Specificity of Detecting Myocardial Ischemia (Reader 3)
大体时间：Day 30

Enrolled subjects were imaged (10 minutes post-injection) using iodofiltic acid I 123 SPECT and the resulting data were reviewed in blinded reads by readers independent of the study centers and the Sponsor. The results obtained in these blinded reads were compared with the final diagnosis for each subject with regard to myocardial ischemia or ACS, determined by the Final Diagnosis Clinical Endpoints Committee (FDCEC).

Sensitivity = % (n/N): N = number of subjects positive for ischemia per the FDCEC; n = subset of N positive for ischemia per the blinded Majority Read (two of three readers) of iodofiltic acid I 123 readers.

Specificity = % (n/N): N = number of subjects negative for ischemia per the FDCEC; n = subset of N negative for ischemia per the blinded Majority Read (two of three readers) of iodofiltic acid I 123 readers.
Day 30

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

Molecular Insight Pharmaceuticals, Inc.

调查人员

  • 研究主任：Norman LaFrance, MD、Molecular Insight Pharmaceuticals, Inc.

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2007年5月1日

初级完成 (实际的)

2008年6月1日

研究完成 (实际的)

2008年12月1日

研究注册日期

首次提交

2007年8月8日

首先提交符合 QC 标准的

2007年8月9日

首次发布 (估计)

2007年8月10日

研究记录更新

最后更新发布 (估计)

2016年3月31日

上次提交的符合 QC 标准的更新

2016年2月29日

最后验证

2016年2月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • MIP-BP23

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅